Composition containing Lactobacillus reuteri ATG-F4 strain as an effective ingredient for treating or inhibiting metastasis of pancreatic cancer

Lactobacillus reuteri ATG-F4 strain, when combined with chemotherapy, enhances apoptosis and inhibits metastasis markers, effectively reducing pancreatic cancer tumor growth and metastasis while minimizing side effects.

KR1020260161997APending Publication Date: 2026-11-10ATOGEN CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
KR1020250058064
Authority / Receiving Office
KR · KR
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-05-02
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Current treatments for pancreatic cancer, particularly cytotoxic chemotherapy drugs, are limited in efficacy and safety, with high side effects and inadequate suppression of metastasis, necessitating the development of safer and more effective adjuvant therapies.

Method used

A composition containing Lactobacillus reuteri ATG-F4 strain, combined with conventional chemotherapy agents, enhances the expression of apoptosis factor Caspase-3 and tumor metastasis inhibitors Claudin and E-cadherin while reducing Vimentin expression, thereby inhibiting pancreatic cancer growth and metastasis.

Benefits of technology

The combination significantly reduces tumor weight by 60-90% and almost entirely suppresses metastasis, with enhanced protein expression and reduced side effects such as diarrhea, demonstrating the strain's role as a booster for anticancer drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PAT00005_ABST
    Figure PAT00005_ABST
Patent Text Reader

Abstract

The present invention relates to a composition for the treatment of pancreatic cancer or inhibition of metastasis comprising the strain Lactobacillus reuteri ATG-F4 (Lactobacillus reuteriATG-F4, accession number KCTC13717BP). In tumor / metastatic tissues of various cancers, the production of Caspase-3 fragments increases, while Claudin and E-cadherin decrease and Vimentin increases; upon treatment with anticancer drugs, anticancer efficacy is confirmed through the reaction or inhibition of these substances. In the present invention, it is confirmed that in pancreatic cancer and metastatic tissues, compared to a group treated with an anticancer drug alone, the expression of caspase-3 fragment, claudin, and E-cadherin is further increased in a group treated with the combination of the anticancer drug and the Lactobacillus reuteri ATG-F4 strain, and the efficacy of inhibiting the expression of vimentin is also enhanced. These results suggest that the Lactobacillus reuteri ATG-F4 strain of the present invention can be used as a booster for various anticancer drugs and metastasis inhibitors for the treatment of pancreatic cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to Lactobacillus reuteri ATG-F4 ( Lactobacillus reuteri The present invention relates to a composition for the treatment of pancreatic cancer or inhibition of metastasis, characterized by containing the strain ATG-F4 (accession number KCTC13717BP) as an active ingredient. Background Technology

[0002] Cancer, a malignant tumor that threatens human health, ranks as the first or second leading cause of death globally and is the most common cause of death in Western societies, second only to cardiovascular disease. Lung cancer is on the rise due to the aging population, increased smoking rates, and air pollution in modern society. Furthermore, pancreatic, colorectal, breast, and prostate cancers are on a continuous upward trend due to the Westernization of dietary habits, including the consumption of high-fat diets, increased exposure to environmental pollutants, and higher alcohol consumption. Consequently, there is an urgent need to develop anticancer substances that can enable early prevention and treatment of cancer, thereby contributing to the improvement of human health, the enhancement of the quality of a healthy life, and the advancement of public health. Conventional anticancer drugs are primarily cytotoxic agents that exert their anticancer effects through a mechanism in which they directly attack and kill cancer cells. Their main mechanisms of action include DNA damage induction, inhibition of cell division, and metabolic antagonism.

[0003] Meanwhile, pancreatic cancer is a highly fatal malignant tumor, and treatment is extremely difficult because it is often already significantly advanced or metastasized at the time of diagnosis. Early detection is difficult, surgical resection is limited, and survival rates are low despite conventional chemotherapy, with a 5-year survival rate of less than 10%. Due to these characteristics, the prevention and treatment of pancreatic cancer are recognized as critical challenges for the medical community, and there is an urgent need to develop effective and safe prevention and treatment strategies.

[0004] Epithelial-mesenchymal transition (EMT) plays a major role in the malignant progression and metastasis of pancreatic cancer, during which cell adhesion and motility are altered. Key EMT-related biomarkers include Claudin, E-cadherin, and Vimentin. Claudin is a protein that forms tight junctions; a decrease in its expression weakens intercellular binding forces, thereby increasing the invasiveness of cancer cells. E-cadherin is an adhesion protein between epithelial cells, and its reduced expression promotes cell motility and metastasis. Additionally, Vimentin is a mesenchymal cell marker, and increased expression enhances the invasiveness and metastatic ability of cancer cells. Therefore, inhibiting or normalizing changes in the expression of these biomarkers is an important therapeutic strategy capable of effectively suppressing the progression and metastasis of pancreatic cancer.

[0005] Combination chemotherapy with FOLFIRINOX (Folinic acid, 5-Fluorouracil, Irinotecan, Oxaliplatin) or GnP (Gemcitabine, nab-paclitaxel) has been a treatment that has significantly extended the survival time of patients with metastatic pancreatic cancer. However, these cytotoxic anticancer drugs carry a high risk of serious side effects, particularly diarrhea, vomiting, dehydration, and bone marrow suppression, so their use is limited to only a portion of patients in good general condition. Consequently, research is actively underway on safer and more effective adjuvant therapies or alternative treatments.

[0006] It has been reported that probiotics regulate the balance of intestinal microorganisms and play various useful roles. Accordingly, in this invention, we confirmed whether Lactobacillus reuteri ATG-F4 directly acts to regulate the protein expression of the apoptosis factor Caspase-3 fragment and the tumor metastasis factors Claudin, E-cadherin, and Vimentin, and confirmed what positive role it can play in inhibiting the invasion and metastasis of pancreatic cancer cells, thereby completing this invention. Prior art literature

[0007] Republic of Korea Registered Patent No. 10-1951919 (Title of Invention: Novel Lactobacillus reuteri ATG-F4 strain having dopamine secretion-enhancing function, composition for the prevention or treatment of mental disorders containing the same, Applicant: A2Gen Co., Ltd., Registration Date: Feb. 19, 2019) Republic of Korea Registered Patent No. 10-2049700 (Title of Invention: Composition for the prevention or treatment of muscle diseases containing Lactobacillus reuteri ATG-F4, Applicant: A2Gen Co., Ltd., Registration Date: November 21, 2019) The problem to be solved

[0008] The objective of the present invention is Lactobacillus reuteri ATG-F4 ( Lactobacillus reuteri The present invention provides a composition for treating pancreatic cancer or inhibiting metastasis, characterized by containing the strain ATG-F4 (accession number KCTC13717BP) as an active ingredient. means of solving the problem

[0009] The present invention relates to Lactobacillus reuteri ATG-F4 ( Lactobacillus reuteri The present invention relates to a composition for the treatment of pancreatic cancer or inhibition of metastasis, characterized by containing the strain ATG-F4 (accession number KCTC13717BP) as an active ingredient.

[0010] The strain may include one or more selected from the group consisting of the cell, the culture of the strain, the extract, concentrate, and dried product of the culture.

[0011] The above strain increases the expression of the apoptosis factor Caspase-3 fragment protein. It also increases the protein expression of the tumor metastasis factors Claudin and E-cadherin, and inhibits the protein expression of Vimentin.

[0012] The above composition is characterized by the co-administration of a chemical anticancer agent. Preferably, the anticancer agent is oxaliplatin, cisplatin, cyclophosphamide, ifosfide, bendamustine, melphalan, carboplatin, busulfan, dacarbazine, temozolomide, fluorouracil, capecitabine, gemcitabine, doxifluridine, tegafur, cytarabine, azacitidine, decitamine, enositabine, methotrexate, pemetrexid, pralatrexate, cladribine, cloparabine, fludarabine, mercaptopurine, irinotecan, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, etoposide, topotecan, cabazitaxel, paclitaxel, docetaxel, vinblastine, vincristine, vinorelbine, bleomycin, hydroxyurea, and One or more types may be selected from the group consisting of mitomycin C.

[0013] Accordingly, the present invention can provide a pharmaceutical composition for the treatment of pancreatic cancer or inhibition of metastasis containing the above-mentioned Lactobacillus reuteri ATG-F4 strain and a pharmaceutical excipient.

[0014] The present invention will be described in detail below.

[0015] The above anticancer agents are cytotoxic chemotherapy agents that exert an anticancer effect by directly attacking cancer cells that differentiate more rapidly than normal cells; their types include alkylating agents (oxaliplatin, cisplatin, cyclophosphamide, ifosfide, bendamustine, melphalan, carboplatin, busulfan, dacarbazine, temozolomide), metabolic antagonists (fluorouracil, capecitabine, gemcitabine, doxifluridine, tegafur, cytarabine, azacitidine, decitamine, enositabine, methotrexate, pemetrexid, pralatrexate, cladribine, cloparabine, fludarabine, mercaptopurine), and DNA twirlase inhibitors (irinotecan, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, etoposide, topotecan). There are microtubule inhibitors (carbazitaxel, paclitaxel, docetaxel, vinblastine, vincristine, vinorelbine) and others (bleomycin, hydroxyurea, mitomycin C), and the above chemotherapy drugs have similar enzymatic mechanisms of action, primarily through the inhibition of DNA damage or DNA synthesis.

[0016] In the present invention, 1.0 x 10 9 Up to 4.0 x 10 11 Based on the combination of the ATG-F4 strain in CFU and an anticancer drug at a dose of 1–200 mg / kg, tumor weight is reduced by 60–90% compared to the administration of the anticancer drug alone. In addition, tumor metastasis is almost entirely suppressed (approaching 0%).

[0017] The above anticancer agents may be one type or a combination of 2 to 5 types for each anticancer agent. In addition, the dosage of the above anticancer agents is not specifically determined, and the effective concentration may vary depending on the anticancer agent, such as 1~5 mg / kg, 2.5~5 mg / kg, 2.5~5 mg / kg, 2.5~10 mg / kg, 10~25 mg / kg, 10~50 mg / kg, 10~100 mg / kg, 50~100 mg / kg, 10~200 mg / kg, 1~200 mg / kg, etc.

[0018] In addition, when the ATG-F4 strain is administered in combination with the anticancer drug compared to the administration of the anticancer drug alone, the Caspase-3 fragment protein increases 1.7 to 2.0 times. The Claudin protein increased 2.0 to 2.5 times in the group administered in combination with the ATG-F4 strain compared to the administration of the anticancer drug alone, which is a significantly higher result than the value in the tumorigenetic group. Under the same criteria, the E-cadherin protein increased 2.0 to 2.5 times in the group administered in combination with the ATG-F4 strain compared to the group administered with the anticancer drug alone, and the expression of Vimentin is inhibited by 70 to 80% in the group administered in combination with the ATG-F4 strain compared to the group administered alone.

[0019] In the present invention, "culture of a strain" includes a culture medium, such as the culture solution itself cultured in a liquid medium, and the supernatant (filtrate) obtained by filtering and / or centrifuging the culture solution to remove the strain.

[0020] In the present invention, "extracts, concentrates, and dried products of a culture" may undergo centrifugation or filtration processes to remove the liquid culture medium from the culture and recover only the concentrated cells, but the present invention is not limited thereto. Additionally, the concentrated cells may be preserved by drying, freezing, or freeze-drying according to conventional methods so as not to lose their activity.

[0021] The above Lactobacillus reuteri ATG-F4 strain, the cells of the strain, the culture of the strain, the extract, concentrate, and dried product of the culture may be added to the composition of the present invention in an amount of 0.001 to 100 weight%.

[0022] In the present invention, "anticancer chemotherapy" refers to a systemic treatment method that prevents or kills cancer cells by using drugs, namely anticancer agents, for cancer treatment.

[0023] In an embodiment of the present invention, a process is presented for exhibiting anticancer or tumor metastasis-inhibiting efficacy against pancreatic cancer through chemotherapy involving the combined administration of Lactobacillus reuteri ATG-F4 and an anticancer agent. To this end, the growth of pancreatic cancer tumors and metastatic tumors is inhibited by oral administration of Lactobacillus reuteri ATG-F4 and the administration of a combination anticancer agent of FOLFIRINOX (Oxaliplatin, 5-Fluorouracil, Leucovorin, Irinotecan) or GnP (Gemcitabine, Nab-paclitaxel) to mice induced with pancreatic cancer. Due to the use of the combination anticancer agent, it is suggested that the simultaneous use of two or more agents along with the administration of Lactobacillus reuteri ATG-F4 is effective for anticancer or tumor metastasis inhibition.

[0024] In other words, while anticancer or anti-metastatic efficacy is confirmed when conventional anticancer drugs are administered for the treatment of pancreatic cancer, there may be limitations in that cytotoxic anticancer drugs alone cannot inhibit the growth of cancer cells or completely suppress metastasis. However, when Lactobacillus reuteri ATG-F4 is administered in combination with the aforementioned anticancer drug for pancreatic cancer treatment, the expression of apoptosis-related proteins increases, while proteins related to tumor growth / proliferation and tumor metastasis decrease, thereby reducing or decreasing tumor growth. Accordingly, the Lactobacillus reuteri ATG-F4 acts as a 'booster,' 'adjuvant,' or 'amplifier' that promotes or enhances the anticancer or anti-metastatic efficacy of the existing pancreatic cancer anticancer drug. This may also be applicable to various individuals that have developed resistance to various pancreatic cancer anticancer drugs.

[0025] Accordingly, the present invention provides a pharmaceutical composition for the treatment of pancreatic cancer or inhibition of metastasis containing the Lactobacillus reuteri ATG-F4 strain and a pharmaceutical excipient. The composition derived from the Lactobacillus reuteri ATG-F4 strain may be added to the pharmaceutical composition of the present invention in an amount of 0.001 to 100 weight%.

[0026] The above pharmaceutical composition may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, as well as external preparations, suppositories, and sterile injectable solutions, according to conventional methods. Carriers, excipients, and diluents that may be included in the above pharmaceutical composition may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. When formulating, the product is prepared using diluents or excipients such as commonly used fillers, volume expanders, binders, humectants, disintegrants, and surfactants. Solid dosage forms for oral administration include tablets, pills, powders, granules, and capsules; these solid dosage forms are prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose or lactose, or gelatin, with the extract of the present invention. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid dosage forms for oral administration include suspensions, liquids, emulsions, and syrups; in addition to commonly used simple diluents such as water and liquid paraffin, various excipients, such as humectants, sweeteners, flavorings, and preservatives, may be included. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. As non-aqueous solvents and suspending agents, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used. As bases for suppositories, Witepsol, Macrogol, Tween 61, cacao oil, laurin oil, glycerogelatin, etc. may be used.

[0027] The dosage of the pharmaceutical composition of the present invention will vary depending on the age, gender, and weight of the subject to treatment, the specific disease or pathological condition to be treated, the severity of the disease or pathological condition, the route of administration, and the judgment of the prescriber. The determination of the dosage based on these factors is within the level of a person skilled in the art, and a typical dosage is 1.0 x 10⁻⁶ 8 Up to 4.0 x 10 11 ATG-F4 strain in CFU / day, more preferably 1.0 x 10 9 Up to 4.0 x 10 11 ATG-F4 strain CFU / day, most preferably 1.0 x 10 10 Up to 4.0 x 10 11 This is the range of ATG-F4 strains / day in CFU.

[0028] The administration may be performed once a day or divided into several doses. The above dosage does not limit the scope of the present invention in any way.

[0029] The pharmaceutical composition of the present invention can be administered to mammals, such as rats, livestock, and humans, via various routes. Any mode of administration is expected, for example, oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dura mater, or intracerebrovascular injection. Since the composition of the present invention has minimal toxicity and side effects, it is a drug that can be safely used for long-term preventive purposes. Effects of the invention

[0030] The present invention relates to Lactobacillus reuteri ATG-F4 ( Lactobacillus reuteri This invention relates to a composition for the treatment of pancreatic cancer or inhibition of metastasis comprising the strain ATG-F4 (accession number KCTC13717BP).

[0031] In tumor / metastatic tissues of various cancers, the production of Caspase-3 fragments increases, while Claudin and E-cadherin decrease and Vimentin increases; upon treatment with anticancer drugs, anticancer efficacy is confirmed through the reaction or inhibition of these substances.

[0032] In the present invention, it is confirmed that in pancreatic cancer and metastatic tissues, compared to a group treated with an anticancer drug alone, the expression of caspase-3 fragment, claudin, and E-cadherin is further increased in a group treated with the combination of the anticancer drug and the Lactobacillus reuteri ATG-F4 strain, and the efficacy of inhibiting the expression of vimentin is also enhanced.

[0033] These results suggest that the Lactobacillus reuteri ATG-F4 strain of the present invention can be used as a booster for anticancer drugs and metastasis inhibitors for the treatment of various pancreatic cancers. Brief explanation of the drawing

[0034] Figure 1 shows the administration schedule of anticancer agents and the ATG-F4 strain for an animal model of pancreatic cancer (Group I in Figure 1a: FOLFIRINOX and ATG-F4 strain administration group, Group II in Figure 1b: GnP and ATG-F4 strain administration group). Figure 2a shows the results of confirming diarrhea symptoms in a pancreatic cancer animal model after administration of the anticancer agents FOLFIRINOX and ATG-F4 strain (Group I). Figure 2b shows the results of confirming diarrhea symptoms in a pancreatic cancer animal model after administration of the anticancer agents GnP and ATG-F4 strain (Group II). Figure 3a shows a tumor image of a pancreatic cancer animal model after administration of the anticancer agents FOLFIRINOX and ATG-F4 strain, Figure 3b shows the tumor weight, and Figure 3c shows the metastasis rate result graph (Group I). Figure 4a is a tumor image of a pancreatic cancer animal model after administration of the anticancer agents GnP and ATG-F4 strain, and Figure 4b is a tumor weight graph (Group II). Figure 5 shows Western blot results and graphs confirming tumor-associated protein factors expressed in tumors of a pancreatic cancer animal model after administration of the anticancer drug FOLFIRINOX and the ATG-F4 strain. Figure 5a: Caspase-3, Figure 5b: Claudin, Figure 5c: E-cadherin, Figure 5d: Vimentin. Specific details for implementing the invention

[0035] Preferred embodiments of the present invention will be described in detail below. However, the present invention is not limited to the embodiments described herein and may be embodied in other forms. Rather, the content introduced herein is provided to fully convey the concept of the present invention to those skilled in the art, so that it may be thorough and complete.

[0036] <Example 1. Experimental Animals>

[0037] The animal experiments were conducted under the guidance of the Institutional Animal Care and Use Committee (IACUC) of A2GEN Co., Ltd., through appropriate procedures for ethical animal experimentation. The animals used in this experiment were 5-week-old BALB / c nude mice purchased from Raon Bio (Seoul, Korea) (Table 1). PANC-1 cells (human pancreatic cancer cell line, Korean Cell Bank) were cultured in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10% FBS (fetal bovine serum).

[0038] Mice were reared in a room where the indoor temperature was constantly maintained at 23 ± 2℃, temperature and humidity were controlled, and a 12h:12h lighting cycle was maintained. A minimum acclimatization period of 7 days was provided to allow the mice to adapt to the new environment and food, and there were no restrictions on the intake of water and rodent food (Purina).

[0039] After that, the mice were divided into Group I and Group II.

[0040] For Group I, after the acclimatization period, 1.0 x 10 6 PANC-1 cells were administered into and transplanted into the tail of the mouse pancreas, and tumors were allowed to grow for 28 days. FOLFIRINOX (Oxaliplatin 2.5 mg / kg, 5-Fluorouracil 25 mg / kg, Leucovorin (calcium folinate) 50 mg / kg, Irinotecan 25 mg / kg) was administered intraperitoneally, and 4.0 x 10⁶ 10 The ATG-F4 strain of CFU was administered orally every day. The anticancer drug FOLFIRINOX was administered once a week for 36 days, for a total of 6 administrations (Fig. 1).

[0041] For Group II, after the acclimatization period, 1.0 x 10 6 PANC-1 cells were administered and transplanted into the tail of the mouse pancreas, and the tumor was grown for 21 days. Subsequently, GnP (Nab-paclitaxel 1 mg / kg, Gemcitabine 8 mg / kg) was administered intraperitoneally, and 4.0 x 10⁶ 10 ATG-F4 in CFU was administered orally every day. GnP anticancer agent was administered every 4 days for 29 days, for a total of 8 administrations.

[0042] Group I (FOLFIRINOX and ATG-F4 administration models) n number Normal Control (NC) 5 Cancer 4 Cancer + FOLFIRINOX 8 Cancer + FOLFIRINOX + ATG-F4 8

[0043] Group II (GnP and ATG-F4 administration models) n number Normal Control (NC) 4 Cancer 5 Cancer + GnP 5 Cancer + GnP + ATG-F4 5

[0044] <Example 2. Confirmation of Diarrhea Symptoms - Checking for Anticancer Drug Side Effects>

[0045] Since diarrhea is one of the side effects of anticancer drug administration, stool consistency was checked. For this purpose, the stool consistency score (evaluation of improvement in diarrhea symptoms, Table 2) was used as an indicator.

[0046] Stool condition was measured in Group I 30 minutes after the 4th administration of FOLFIRINOX, and in Group II 30 minutes after the 8th administration of GnP.

[0047] score situation Details 0 normal Dry and hard stool 1 Dry, hard stool It is slightly moist and maintains its original shape when pressed with tweezers, and the tweezers go in (break). 2 Less hard stool Less moist and less hard stool (does not crumble) 3 soft stool It is moist and maintains its original shape when pressed with tweezers, but it gets squashed. 4 Soft and slightly diarrhea It is very moist and fails to maintain its original shape when pressed with tweezers, becoming squashed. 5 Severe watery diarrhea High moisture content and lacks stool form from the time of discharge (watery state)

[0048] The results for this are shown in Figure 2, where mice with induced cancer or mice administered an anticancer drug show symptoms of diarrhea.

[0049] This can be described as diarrhea symptoms appearing due to immune disturbance caused by disease or side effects of anticancer drugs. On the other hand, along with anticancer drugs, 4.0 x 10 10 In mice administered the CFU ATG-F4 strain, it is confirmed that the stool consistency score caused by FOLFIRINOX and GnP is lowered.

[0050] Accordingly, it was confirmed that diarrhea symptoms were reduced due to the administration of the ATG-F4 strain, indicating that side effects induced by anticancer drugs were alleviated.

[0051] <Example 3. Confirmation of the condition of mice administered ATG-F4 strain and anticancer drug>

[0052] Each mouse was necropsied by CO2 euthanasia on the last day of the experiment. Photos of the condition of the necropsied mice and the weights of tumors and metastatic tumors in each group are shown in Figures 3 and 4 according to the anticancer drug administration group.

[0053] Example 3-1. Group I: FOLFIRINOX + ATG-F4 administration group

[0054] Looking at Figure 3, it appears that the tumors of the mice in the group not administered the anticancer drug FOLFIRINOX, both metastatic and pancreatic tumors, grew very large overall.

[0055] In mice administered only the chemotherapy drug FOLFIRINOX, the volume of both metastatic and pancreatic tumors decreased, but compared to the group administered the anticancer drug in combination with the ATG-F4 strain, the weight of the tumors decreased by about one-third.

[0056] Example 3-2. Group II: GnP + ATG-F4 administration group

[0057] In Figure 4 as well, it is confirmed that the tumors of the mice in the group that were not administered the anticancer drug GnP grew very large overall. Although the volume of the tumors decreased in mice administered only the chemotherapy drug, when compared to the group administered the chemotherapy drug and the ATG-F4 strain in combination, it is confirmed that the tumor weight decreased to about 1 / 6.

[0058] <Example 4. Confirmation of Pancreatic Cancer Tumor / Anti-Metastasis Related Protein Expression - Western Blot Analysis>

[0059] Protein expression was confirmed in the FOLFIRINOX and ATG-F4 administration groups.

[0060] Mouse pancreatic tumor tissue was placed in RIPA buffer (0.5 M Tris-HCl, pH 7.4, 1.5 M NaCl, 2.5% deoxycholic acid, 10% NP-40) containing a protease inhibitor cocktail (Millipore, USA) and chopped with scissors. Subsequently, the tissue was separated in a centrifuge at 17,548 xg at 4°C for 10 minutes, and the supernatant was collected. The protein concentration in the supernatant was measured using a BCA assay (Thermo Fisher, USA). The protein extract (40 µg) was separated using an 8% or 10% polyacrylamide mini-gel and transferred to a PVDF membrane (Bio-Rad, USA). The transferred PVDF membrane was incubated overnight at 4°C with a primary antibody diluted 1:1000 in SuperBlock (PBS) Blocking buffer. The primary antibodies analyzed were apoptosis factors (Caspase-3, Cleaved caspase-3) and metastasis-related factors (Claudin, E-cadherin, Vimentin). The PVDF membrane was washed four times with 0.1% Tween TBS and then incubated for 1 hour at room temperature in 0.1% Tween TBS buffer containing 3% BSA (Bovogen, USA) along with goat anti-rabbit IgG HRP conjugated secondary antibody (Bio-Rad, USA). After thorough washing with 0.1% Tween TBS, the immunostained bands were visualized using ECL (Bio-Rad, USA). Target proteins were identified using the ChemiDoc™ Imaging System (Bio-Rad, USA), and band intensity was quantified using Image Lab™ software (Bio-Rad, USA). The results are shown in Figure 5.

[0061] The expression levels of apoptosis and metastasis-related proteins in pancreatic cancer tissue showed a distinct increase or decrease due to the administration of the ATG-F4 strain. When the anticancer drug and the ATG-F4 strain were administered in combination (Cancer+FFX+ATG-F4), the protein expression of the Caspase-3 fragment increased by more than twofold compared to mice treated with the anticancer drug alone, confirming that the ATG-F4 strain has excellent anticancer booster efficacy.

[0062] In the results of Figure 5b, there was no significant difference in the expression of Claudin when the anticancer drug FOLFIRINOX (Cancer+FFX) was administered compared to tumor tissue (Cancer), but it increased significantly when the anticancer drug and the ATG-F4 strain were administered together (Cancer+FFX+ATG-F4).

[0063] In the results of Figure 5c, it can be seen that although the expression of E-cadherin increased when the anticancer drug FOLFIRINOX was administered alone (Cancer+FFX) compared to tumor tissue (Cancer), when the anticancer drug and the ATG-F4 strain were administered in combination (Cancer+FFX+ATG-F4), it increased significantly by more than twofold compared to treatment with the anticancer drug alone.

[0064] Meanwhile, in Figure 5d, compared to tumor tissue (Cancer), Vimentin is reduced when the anticancer drug is administered alone (Cancer+FFX), but is almost not expressed when the anticancer drug and the ATG-F4 strain are administered together (Cancer+FFX+ATG-F4), confirming the excellent combination effect of the ATG-F4 strain.

[0065] Accordingly, it can be confirmed through the present invention that ATG-F4 very efficiently boosts the efficacy of cytotoxic combination anticancer agents in inhibiting pancreatic cancer cell death and metastasis.

Claims

Claim 1 Lactobacillus reuteri ATG-F4( Lactobacillus reuteri A composition for treating pancreatic cancer or inhibiting metastasis, characterized by containing the strain ATG-F4 (accession number KCTC13717BP) as an active ingredient. Claim 2 A composition for treating pancreatic cancer or inhibiting metastasis according to claim 1, characterized in that the strain comprises one or more selected from the group consisting of the cell, the culture of the strain, the extract, the concentrate, and the dried product of the culture. Claim 3 A composition for treating pancreatic cancer or inhibiting metastasis according to claim 1, characterized in that the composition increases the protein expression of a Caspase-3 fragment, Claudin, or E-cadherin, and inhibits the protein expression of Vimentin. Claim 4 A composition for treating pancreatic cancer or inhibiting metastasis, characterized in that a chemical anticancer agent is administered in combination with the composition in claim 1. Claim 5 In paragraph 4, the chemical anticancer agent is oxaliplatin, cisplatin, cyclophosphamide, ifosfide, bendamustine, melphalan, carboplatin, busulfan, dacarbazine, temozolomide, fluorouracil, capecitabine, doxifluridine, tegafur, cytarabine, azacitidine, decitamine, enositabine, methotrexate, pemetrexid, pralatrexate, cladribine, cloparabine, fludarabine, gemcitabine, mercaptopurine, irinotecan, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, etoposide, topotecan, cabazitaxel, paclitaxel, docetaxel, vinblastine, vincristine, vinorelbine, bleomycin, hydroxyurea, and A composition for treating pancreatic cancer or inhibiting metastasis, characterized by being selected from the group consisting of mitomycin C, or one or more. Claim 6 A composition for treating pancreatic cancer or inhibiting metastasis, characterized in that it reduces symptoms of diarrhea caused by the administration of an anticancer drug, as described in claim 1. Claim 7 A pharmaceutical composition for the treatment of pancreatic cancer or inhibition of metastasis containing the composition of claim 1 and pharmaceutical excipients.